BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20260419T012836
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:7521-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20260419T012836
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:27418-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20260419T012836
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:7657-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20260419T012836
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:27421-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200124T090000
DTEND;TZID=America/New_York:20200124T113000
DTSTAMP:20260419T012836
CREATED:20200102T191157Z
LAST-MODIFIED:20200102T191157Z
UID:7659-1579856400-1579865400@scienceinboston.com
SUMMARY:Don't Screw It Up - Choosing The Right Consultant: Important Considerations in Selecting the Right Regulatory and Quality Consultants for Your Projects
DESCRIPTION:Larger pharma company regulatory affairs and quality departments are constantly being asked to do more with no increase in resources. Smaller companies and foreign companies often do not have any or enough US based staff or staff with the appropriate expertise to meet their business goals. Thus the use of consultants to provide assistance is a significant and growing trend in both the pharmaceutical and medical device industries. \nBut how does one go about choosing a consultant group? Use a big CRO-type organization? Contact a single proprietor? Are there alternatives to consider in terms of therapeutic area\, geography\, on-site or remote work\, other potential add–on services that are offered\, etc.? This session will present the perspectives and learnings of a senior regulatory affairs executive with decades of successful experience and who has worked in both pharma and the consultancy industries. Similarly\, the second presenter will be a long-standing quality and compliance professional. \nIn choosing and utilizing regulatory and quality consultants for both tactical and strategic activities there are many attributes to consider. What information should you provide to allow a consultant to appropriately scope out\, determine timelines and resources\, and price a project? How should one compare proposals from different consultants? What should you verify with a consultant before signing the contract? An experienced consultancy executive will provide these insights and advise participants on what is needed to make the relationship work smoothly so that your objectives are fully realized. \nUse of regulatory affairs and quality consultants in the device/pharma industry is projected to continue to increase by 10% or more annually. Intermediate and senior level attendees will be able to apply the information shared during the presentations and Q&A session in their normal work activities as they consider adding consultants to complete business objectives. \nLearning Objectives: \n• Describe the key considerations in choosing an appropriate regulatory and quality consultant to meet business objectives. \n• Explain to a potential regulatory or quality consultant the essential aspects of a project that will allow an achievable timeline\, service delivery\, and budget to be presented for consideration. \nYour presenters will be Andrew S. Verderame\, Partner\, PharmaLex US Corporation and Gerardo Gomez\, Sr. Director Quality & Compliance\, PharmaLex US Corporation. \nA light breakfast will be served and there will be plenty of time for Q & A at the conclusion of the presentation.
URL:https://scienceinboston.com/event/dont-screw-it-up-choosing-the-right-consultant-important-considerations-in-selecting-the-right-regulatory-and-quality-consultants-for-your-projects/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200124T090000
DTEND;TZID=America/New_York:20200124T113000
DTSTAMP:20260419T012836
CREATED:20200102T191157Z
LAST-MODIFIED:20200102T191157Z
UID:27422-1579856400-1579865400@scienceinboston.com
SUMMARY:Don't Screw It Up - Choosing The Right Consultant: Important Considerations in Selecting the Right Regulatory and Quality Consultants for Your Projects
DESCRIPTION:Larger pharma company regulatory affairs and quality departments are constantly being asked to do more with no increase in resources. Smaller companies and foreign companies often do not have any or enough US based staff or staff with the appropriate expertise to meet their business goals. Thus the use of consultants to provide assistance is a significant and growing trend in both the pharmaceutical and medical device industries. \nBut how does one go about choosing a consultant group? Use a big CRO-type organization? Contact a single proprietor? Are there alternatives to consider in terms of therapeutic area\, geography\, on-site or remote work\, other potential add–on services that are offered\, etc.? This session will present the perspectives and learnings of a senior regulatory affairs executive with decades of successful experience and who has worked in both pharma and the consultancy industries. Similarly\, the second presenter will be a long-standing quality and compliance professional. \nIn choosing and utilizing regulatory and quality consultants for both tactical and strategic activities there are many attributes to consider. What information should you provide to allow a consultant to appropriately scope out\, determine timelines and resources\, and price a project? How should one compare proposals from different consultants? What should you verify with a consultant before signing the contract? An experienced consultancy executive will provide these insights and advise participants on what is needed to make the relationship work smoothly so that your objectives are fully realized. \nUse of regulatory affairs and quality consultants in the device/pharma industry is projected to continue to increase by 10% or more annually. Intermediate and senior level attendees will be able to apply the information shared during the presentations and Q&A session in their normal work activities as they consider adding consultants to complete business objectives. \nLearning Objectives: \n• Describe the key considerations in choosing an appropriate regulatory and quality consultant to meet business objectives. \n• Explain to a potential regulatory or quality consultant the essential aspects of a project that will allow an achievable timeline\, service delivery\, and budget to be presented for consideration. \nYour presenters will be Andrew S. Verderame\, Partner\, PharmaLex US Corporation and Gerardo Gomez\, Sr. Director Quality & Compliance\, PharmaLex US Corporation. \nA light breakfast will be served and there will be plenty of time for Q & A at the conclusion of the presentation.
URL:https://scienceinboston.com/event/dont-screw-it-up-choosing-the-right-consultant-important-considerations-in-selecting-the-right-regulatory-and-quality-consultants-for-your-projects-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T080000
DTEND;TZID=America/New_York:20200207T170000
DTSTAMP:20260419T012836
CREATED:20191209T231811Z
LAST-MODIFIED:20191209T231811Z
UID:7529-1580025600-1581094800@scienceinboston.com
SUMMARY:Program for Chairs of Clinical Services
DESCRIPTION:Overview\n\nChairs of major clinical departments traditionally have faced complex responsibilities because of their multiple tasks – patient care\, teaching\, research\, and administration. \nAs a result of the effects of health reform\, financial pressures\, and resource constraints\, many chairs are being asked by their institutions to become more extensively involved in institutional decision-making with regard to programs\, staffing\, operating and capital budgets\, and other issues\, such as the restructuring of the clinical enterprise. These responsibilities are in addition to their traditional concerns within their own departments. At the same time\, chairs have to consider to a greater degree the relationship between institutional priorities\, departmental decisions\, and collaboration with other services. These new tasks call for new leadership and managerial skills. \nThe Program for Chairs of Clinical Services brings together chairs of major clinical departments in teaching hospitals and health systems and an experienced interdisciplinary faculty for two weeks of intensive and systematic study of some of the critical leadership and management issues facing chairs\, their departments\, and teaching hospitals. \nCurriculum \nThe curriculum of the program is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nHealth Policy\nFinancial Analysis and Control\nOperations Management\nOrganizational Issues\nLeadership Challenges\n\nA carefully integrated curriculum permits participants to examine fundamental managerial issues from the perspective of several disciplines. A new program initiative or downsizing proposal\, for example\, may raise managerial problems concerning departmental and institutional strategy; the application and utility of systems analysis and quantitative analytical methods; basic economic trends and legal constraints; financial analysis and control; and organizational behavior\, design\, and development. \nThe overriding purpose for learning concepts\, techniques\, and skills in any of the management disciplines in this program is to understand their managerial use and limitations. For example\, the course in financial analysis and control does not aim to develop expert accountants or to provide accounting skills\, per se. The purpose in learning to analyze the cost and financial implications of program decisions\, for instance\, is: (a) to better understand the fundamental methodological issues involved\, the driving factors behind any particular analysis\, the limits of such analysis\, and the need to blend this with clinical\, strategic\, and other non-financial judgements; and (b) to improve the ability of a participant both to manage staff and to interact more effectively with the fiscal affairs personnel in their hospital\, health system\, or medical school. \nTeaching Method \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at Harvard Business School. Most of the cases present actual problem situations familiar to chairs of clinical departments. Special case materials based on field studies of specific issues faced by service chairs have been and continue to be prepared by the faculty. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and forces the participant to choose a course of action. Participants go through a three-step study process. First\, participants study each case independently. Participants then meet in small discussion groups to test their individual analyses against those of their peers. Finally\, the entire class discusses the case\, with the professor as catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and faculty. \nProgram Organization \nClasses and discussion groups are scheduled six days a week. Preparation for classes averages six hours a day. Registration is scheduled for 3:00 – 4:00 pm on the opening Sunday of the program. The following Sunday is free except for cases to be prepared for Monday’s classes. The program concludes on the second Friday at 2:00 pm. Participants are required to free themselves of professional and family responsibilities for the period of the program so that full attention can be devoted to the educational experience.
URL:https://scienceinboston.com/event/program-for-chairs-of-clinical-services/
LOCATION:Harvard Longwood Campus\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200126T080000
DTEND;TZID=America/New_York:20200207T170000
DTSTAMP:20260419T012836
CREATED:20191209T231811Z
LAST-MODIFIED:20191209T231811Z
UID:27420-1580025600-1581094800@scienceinboston.com
SUMMARY:Program for Chairs of Clinical Services
DESCRIPTION:Overview\n\nChairs of major clinical departments traditionally have faced complex responsibilities because of their multiple tasks – patient care\, teaching\, research\, and administration. \nAs a result of the effects of health reform\, financial pressures\, and resource constraints\, many chairs are being asked by their institutions to become more extensively involved in institutional decision-making with regard to programs\, staffing\, operating and capital budgets\, and other issues\, such as the restructuring of the clinical enterprise. These responsibilities are in addition to their traditional concerns within their own departments. At the same time\, chairs have to consider to a greater degree the relationship between institutional priorities\, departmental decisions\, and collaboration with other services. These new tasks call for new leadership and managerial skills. \nThe Program for Chairs of Clinical Services brings together chairs of major clinical departments in teaching hospitals and health systems and an experienced interdisciplinary faculty for two weeks of intensive and systematic study of some of the critical leadership and management issues facing chairs\, their departments\, and teaching hospitals. \nCurriculum \nThe curriculum of the program is organized around the following interrelated courses taught by a faculty experienced in executive education for physicians and other key decision-makers in the health system: \n\nInstitutional Strategy\nHealth Policy\nFinancial Analysis and Control\nOperations Management\nOrganizational Issues\nLeadership Challenges\n\nA carefully integrated curriculum permits participants to examine fundamental managerial issues from the perspective of several disciplines. A new program initiative or downsizing proposal\, for example\, may raise managerial problems concerning departmental and institutional strategy; the application and utility of systems analysis and quantitative analytical methods; basic economic trends and legal constraints; financial analysis and control; and organizational behavior\, design\, and development. \nThe overriding purpose for learning concepts\, techniques\, and skills in any of the management disciplines in this program is to understand their managerial use and limitations. For example\, the course in financial analysis and control does not aim to develop expert accountants or to provide accounting skills\, per se. The purpose in learning to analyze the cost and financial implications of program decisions\, for instance\, is: (a) to better understand the fundamental methodological issues involved\, the driving factors behind any particular analysis\, the limits of such analysis\, and the need to blend this with clinical\, strategic\, and other non-financial judgements; and (b) to improve the ability of a participant both to manage staff and to interact more effectively with the fiscal affairs personnel in their hospital\, health system\, or medical school. \nTeaching Method \nThe principal method of instruction in the program is the case method\, a technique pioneered and refined at Harvard Business School. Most of the cases present actual problem situations familiar to chairs of clinical departments. Special case materials based on field studies of specific issues faced by service chairs have been and continue to be prepared by the faculty. \nThe case method confronts the participant with an actual management problem\, halted at a point where decisions must be made\, and forces the participant to choose a course of action. Participants go through a three-step study process. First\, participants study each case independently. Participants then meet in small discussion groups to test their individual analyses against those of their peers. Finally\, the entire class discusses the case\, with the professor as catalyst and guide. The professor points out considerations the class has overlooked; elicits from participants the lessons of experience; pursues each line of investigation to its conclusion; and finally\, summarizes the discussion and draws out the major lessons it has taught. \nAssigned readings and guest lecturers supplement and augment the use of cases. In addition\, an important part of the learning process occurs during the informal exchange of insights and experience among participants and faculty. \nProgram Organization \nClasses and discussion groups are scheduled six days a week. Preparation for classes averages six hours a day. Registration is scheduled for 3:00 – 4:00 pm on the opening Sunday of the program. The following Sunday is free except for cases to be prepared for Monday’s classes. The program concludes on the second Friday at 2:00 pm. Participants are required to free themselves of professional and family responsibilities for the period of the program so that full attention can be devoted to the educational experience.
URL:https://scienceinboston.com/event/program-for-chairs-of-clinical-services-2/
LOCATION:Harvard Longwood Campus\, Boston\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200128T150000
DTEND;TZID=America/New_York:20200128T170000
DTSTAMP:20260419T012836
CREATED:20200102T191348Z
LAST-MODIFIED:20200102T191348Z
UID:7662-1580223600-1580230800@scienceinboston.com
SUMMARY:First Annual “Patient Safety in a Digital World” Symposium
DESCRIPTION:The Foundation for the Innovation and Development of Health Safety (FIDHS) is pleased to convene our 1st Annual International Patient Safety Symposium at Dana-Farber Cancer Institute in Boston. In an effort to move the needle on patient safety\, the symposium will convene thought leaders in digital health innovation\, hospital CEOs and their pharmacy leaders\, and patient safety executives from across the U.S. and Europe to address the latest digital strategies that ensure patient safety for hospitals\, insurers\, and pharma manufacturers. The symposium provides a global platform for medical professionals and innovators to collaborate on a vision of patient safety in a digital world\, providing insights and recommendations based on real world digital programs. \nMassBio President & CEO Robert K. Coughlin will deliver the Closing Keynote. Register to attend the event. \nAgenda Outline \n\n\n3:00 – 3:15 PM Welcome/Refreshments \n3:15 – 3:30 PM Opening Remarks \n3:30 – 4:15 PM Executive Panel Discussion: “Patient Safety\, International Considerations & Lessons Learned” \n4:15 – 4:45 PM Special Guest Speaker \n4:45 – 5:30 PM Executive Panel Discussion: “Safety in a Digital World\, Opportunities for Disruption” \n5:30 – 6:00 PM Closing Remarks \n6:00 – 8:00 PM Cocktail/Networking Reception
URL:https://scienceinboston.com/event/first-annual-patient-safety-in-a-digital-world-symposium/
LOCATION:Dana Farber Cancer Institute\, 450 Brookline Avenue\, Yawkey Center for Cancer Care\, Lavine Family Dining Pavilion\, 3rd Floor\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200128T150000
DTEND;TZID=America/New_York:20200128T170000
DTSTAMP:20260419T012836
CREATED:20200102T191348Z
LAST-MODIFIED:20200102T191348Z
UID:27423-1580223600-1580230800@scienceinboston.com
SUMMARY:First Annual “Patient Safety in a Digital World” Symposium
DESCRIPTION:The Foundation for the Innovation and Development of Health Safety (FIDHS) is pleased to convene our 1st Annual International Patient Safety Symposium at Dana-Farber Cancer Institute in Boston. In an effort to move the needle on patient safety\, the symposium will convene thought leaders in digital health innovation\, hospital CEOs and their pharmacy leaders\, and patient safety executives from across the U.S. and Europe to address the latest digital strategies that ensure patient safety for hospitals\, insurers\, and pharma manufacturers. The symposium provides a global platform for medical professionals and innovators to collaborate on a vision of patient safety in a digital world\, providing insights and recommendations based on real world digital programs. \nMassBio President & CEO Robert K. Coughlin will deliver the Closing Keynote. Register to attend the event. \nAgenda Outline \n\n\n3:00 – 3:15 PM Welcome/Refreshments \n3:15 – 3:30 PM Opening Remarks \n3:30 – 4:15 PM Executive Panel Discussion: “Patient Safety\, International Considerations & Lessons Learned” \n4:15 – 4:45 PM Special Guest Speaker \n4:45 – 5:30 PM Executive Panel Discussion: “Safety in a Digital World\, Opportunities for Disruption” \n5:30 – 6:00 PM Closing Remarks \n6:00 – 8:00 PM Cocktail/Networking Reception
URL:https://scienceinboston.com/event/first-annual-patient-safety-in-a-digital-world-symposium-2/
LOCATION:Dana Farber Cancer Institute\, 450 Brookline Avenue\, Yawkey Center for Cancer Care\, Lavine Family Dining Pavilion\, 3rd Floor\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200130T170000
DTEND;TZID=America/New_York:20200130T190000
DTSTAMP:20260419T012836
CREATED:20200102T191715Z
LAST-MODIFIED:20200102T191715Z
UID:7665-1580403600-1580410800@scienceinboston.com
SUMMARY:MassBio Young Professionals Event: Trivia Night
DESCRIPTION:Join MassBio and FUJIFILM for Trivia Night! Rounds will cover: music\, movies\, TV\, science\, technology\, history\, literature\, Star Wars\, Harry Potter\, etc. Grab a drink and show off your smarts\, all while networking. Space is limited. Drinks and appetizers will be provided. MassBio Members only. This event is being held at FUJIFILM: One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA.
URL:https://scienceinboston.com/event/massbio-young-professionals-event-trivia-night/
LOCATION:FUJIFILM\, One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200130T170000
DTEND;TZID=America/New_York:20200130T190000
DTSTAMP:20260419T012836
CREATED:20200102T191715Z
LAST-MODIFIED:20200102T191715Z
UID:27424-1580403600-1580410800@scienceinboston.com
SUMMARY:MassBio Young Professionals Event: Trivia Night
DESCRIPTION:Join MassBio and FUJIFILM for Trivia Night! Rounds will cover: music\, movies\, TV\, science\, technology\, history\, literature\, Star Wars\, Harry Potter\, etc. Grab a drink and show off your smarts\, all while networking. Space is limited. Drinks and appetizers will be provided. MassBio Members only. This event is being held at FUJIFILM: One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA.
URL:https://scienceinboston.com/event/massbio-young-professionals-event-trivia-night-2/
LOCATION:FUJIFILM\, One Kendall Square\, Binney St. Building 400\, First Floor\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T170000
DTEND;TZID=America/New_York:20200204T203000
DTSTAMP:20260419T012836
CREATED:20200102T201953Z
LAST-MODIFIED:20200102T201953Z
UID:7672-1580835600-1580848200@scienceinboston.com
SUMMARY:Venture Funding Happy Hour at M2D2!
DESCRIPTION:Startups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nThis happy hour event will bring your startup one step closer to your business goals. Get a crystal-clear picture of the process as we welcome four noted life science business financing experts to our Lowell center after work on Tuesday\, February 4th. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Venture Capital Panel with Bill Yelle\, Nancy Briefs\, Maria Berkman\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2020 Info Session* \n*Free parking included* \n  \n  \nMeet the Panel: \n  \n  \nVinit Nijhawan is Interim Executive Director at Massachusetts Technology Transfer Center in UMass President’s Office. Vinit was Managing Director at UnitedLex focused on academic IP commercialization. Vinit was Managing Director\, Office of Technology Development at Boston University where he launched 8 venture-backed spinoffs and successfully executed a patent monetization program. Vinit teaches MBA courses on Entrepreneurship at BU Questrom School of Business\, over 450 students have taken his courses. Vinit has over 30 years experience building five startups: as CEO of three\, five were acquired. Vinit was Venture Partner at Key Venture Partners and his one investment was acquired for $430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 240 panel discussions and paper presentations\, and was a Board Member of Mass Ventures\, an early stage\, quasi-public Massachusetts venture capital firm\, a co-founder of EdTech Accelerator/Incubator LearnLaunch\, ex-President of Massachusetts Association of Technology Transfer Offices and co-founder of Waterloo Alumni Angels. Vinit is also serving or has served on non-profit boards of VentureCafe Foundation\, National Academy of Inventors\, TiE Global. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario\, Canada. \n________________________________________________________________________________________________________________ \nNancy Briefs‘ background includes 35+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm-shifting technologies with six (6) prior MedTech startups. Having raised over $500M in capital and six successful liquidity events (including an IPO with Goldman) she has proven the ability to lead teams from concept thru commercialization and value creation. She has served on the Boards of: HealthHelm\, Digital Cognition Technologies\, InfoBionic\, MyndBlu\, CardiAQ Valve Technologies\, MDMA (Medical Device and Manufacturers Association)\, Apama Medical\, Direct Flow Medical\, Eleme Medical\, and Percardia. \nAn entrepreneur inventor she is listed on seven issued and two pending US patents. \nNancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University. \n________________________________________________________________________________________________________________ \nWilliam E. Yelle \nEntrepreneur in Residence at Partners Innovation \nBill has spent over 30 years in the biopharmaceutical industry\, with experience ranging from large pharma to early stage\, venture-backed companies. He currently serves as Executive Chairman of Envisia Therapeutics\, as well as an advisor to several entrepreneurial startups. He is also an adjunct faculty member at the Manning School of Business. \nPrior to Envisia\, Bill served as CEO of Aldea Pharmaceuticals\, where he built an executive team\, completed a successful $28 M Series B raise and brought two programs into the clinic. Prior to Aldea\, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor\, Bill was instrumental in the companies’ transition from an early stage clinical organization with just over 30 employees into a fully integrated pharmaceutical company consisting of close to 3\,000. At Sepracor\, he was responsible for the consummation of over 30 material transactions\, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. Prior to joining Sepracor in 1995\, Bill held various positions of increasing responsibility in Pfizer’s U.S\, Pharmaceuticals Group. \nIn addition to working as Executive Chair at Envisia\, Bill has served on the boards of LQ3 Pharma and Aldea Pharmaceuticals. \nBill has an M.B.A. in Management/Marketing from Columbia University\, a M.S. in Organic Chemistry from the University of California at Berkeley and a B.S. Cum Laude from the University of Massachusetts Lowell. \n______________________________________________________________________________________________________ \nMaria Berkman\, MD\, MBA\, \nDirector\, and Head of the MedTech practice\, Broadview Ventures. \nMaria shares responsibility for all aspects of Broadview’s investment activity\, from identification and screening of new opportunities\, through due diligence\, negotiation of deal structure\, and portfolio company board involvement. \nPrior to joining Broadview Ventures\, Maria was a management consultant at Monitor Group\, where she specialized in life sciences with a focus on corporate\, franchise\, and asset-level commercialization strategy and competitive strategic planning for both BioPharma and MedTech clients. Prior to joining Monitor Group\, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine\, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery\, and earned an MBA from the Anderson School of Management at UCLA. \nMaria serves on the boards of Adient\, Aria CV\, AtaCor\, FineHeart\, Vascular Graft Solutions and Vectorious\, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR). \nIn addition to her role at Broadview Ventures\, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv\, Israel.
URL:https://scienceinboston.com/event/venture-funding-happy-hour-at-m2d2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200204T170000
DTEND;TZID=America/New_York:20200204T203000
DTSTAMP:20260419T012836
CREATED:20200102T201953Z
LAST-MODIFIED:20200102T201953Z
UID:27426-1580835600-1580848200@scienceinboston.com
SUMMARY:Venture Funding Happy Hour at M2D2!
DESCRIPTION:Startups: If you’re committed to your business vision\, then you MUST start planning for venture financing. \nEven if your startup is brand-new\, NOW is the time to map out your complete business growth path — all the way to venture financing. \nThis happy hour event will bring your startup one step closer to your business goals. Get a crystal-clear picture of the process as we welcome four noted life science business financing experts to our Lowell center after work on Tuesday\, February 4th. \nJoin us and: \n\nUnderstand how venture financing works today.\nLearn what to look for (and look OUT for) in a VC offer.\nLearn how to prepare your full business financing plan—from angel investors to VCs.\nFind out the preparations you need to make to advance to each stage of financing.\nGet expert answers to all your business financing questions.\nNetwork with VCs\, other investors\, and your entrepreneur peers.\nEnjoy complimentary snacks and beverages.\n\nPLUS\, practice and improve your pitch! \nCome with your pitch deck\, because you can enter your name to give your business presentation and get valuable feedback from our panel. \nAgenda: \n5:00 – Registration & Networking w/ food & drink \n5:30 – Venture Capital Panel with Bill Yelle\, Nancy Briefs\, Maria Berkman\, and moderator Vinit Nijhawan. \n6:30 – Q&A and Networking \n  \n  \nOnline tickets: $10.00 \nWalk-ins: $20.00 \n*This event will also include a 200k Challenge 2020 Info Session* \n*Free parking included* \n  \n  \nMeet the Panel: \n  \n  \nVinit Nijhawan is Interim Executive Director at Massachusetts Technology Transfer Center in UMass President’s Office. Vinit was Managing Director at UnitedLex focused on academic IP commercialization. Vinit was Managing Director\, Office of Technology Development at Boston University where he launched 8 venture-backed spinoffs and successfully executed a patent monetization program. Vinit teaches MBA courses on Entrepreneurship at BU Questrom School of Business\, over 450 students have taken his courses. Vinit has over 30 years experience building five startups: as CEO of three\, five were acquired. Vinit was Venture Partner at Key Venture Partners and his one investment was acquired for $430M. Vinit is an advisor and board member to several technology startups and was a Mass High Tech All-Star in 2005. Vinit has participated in over 240 panel discussions and paper presentations\, and was a Board Member of Mass Ventures\, an early stage\, quasi-public Massachusetts venture capital firm\, a co-founder of EdTech Accelerator/Incubator LearnLaunch\, ex-President of Massachusetts Association of Technology Transfer Offices and co-founder of Waterloo Alumni Angels. Vinit is also serving or has served on non-profit boards of VentureCafe Foundation\, National Academy of Inventors\, TiE Global. Vinit earned a B.A.Sc in electrical engineering from the University of Waterloo in Ontario\, Canada. \n________________________________________________________________________________________________________________ \nNancy Briefs‘ background includes 35+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm-shifting technologies with six (6) prior MedTech startups. Having raised over $500M in capital and six successful liquidity events (including an IPO with Goldman) she has proven the ability to lead teams from concept thru commercialization and value creation. She has served on the Boards of: HealthHelm\, Digital Cognition Technologies\, InfoBionic\, MyndBlu\, CardiAQ Valve Technologies\, MDMA (Medical Device and Manufacturers Association)\, Apama Medical\, Direct Flow Medical\, Eleme Medical\, and Percardia. \nAn entrepreneur inventor she is listed on seven issued and two pending US patents. \nNancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia University. \n________________________________________________________________________________________________________________ \nWilliam E. Yelle \nEntrepreneur in Residence at Partners Innovation \nBill has spent over 30 years in the biopharmaceutical industry\, with experience ranging from large pharma to early stage\, venture-backed companies. He currently serves as Executive Chairman of Envisia Therapeutics\, as well as an advisor to several entrepreneurial startups. He is also an adjunct faculty member at the Manning School of Business. \nPrior to Envisia\, Bill served as CEO of Aldea Pharmaceuticals\, where he built an executive team\, completed a successful $28 M Series B raise and brought two programs into the clinic. Prior to Aldea\, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). While at Sepracor\, Bill was instrumental in the companies’ transition from an early stage clinical organization with just over 30 employees into a fully integrated pharmaceutical company consisting of close to 3\,000. At Sepracor\, he was responsible for the consummation of over 30 material transactions\, the most notable being the company’s sale to Dainippon Sumitomo Pharma for $2.6 billion in 2009. Prior to joining Sepracor in 1995\, Bill held various positions of increasing responsibility in Pfizer’s U.S\, Pharmaceuticals Group. \nIn addition to working as Executive Chair at Envisia\, Bill has served on the boards of LQ3 Pharma and Aldea Pharmaceuticals. \nBill has an M.B.A. in Management/Marketing from Columbia University\, a M.S. in Organic Chemistry from the University of California at Berkeley and a B.S. Cum Laude from the University of Massachusetts Lowell. \n______________________________________________________________________________________________________ \nMaria Berkman\, MD\, MBA\, \nDirector\, and Head of the MedTech practice\, Broadview Ventures. \nMaria shares responsibility for all aspects of Broadview’s investment activity\, from identification and screening of new opportunities\, through due diligence\, negotiation of deal structure\, and portfolio company board involvement. \nPrior to joining Broadview Ventures\, Maria was a management consultant at Monitor Group\, where she specialized in life sciences with a focus on corporate\, franchise\, and asset-level commercialization strategy and competitive strategic planning for both BioPharma and MedTech clients. Prior to joining Monitor Group\, Maria trained within the Partners HealthCare System at Newton Wellesley Hospital in General Surgery. Maria earned an MD from the UCLA School of Medicine\, graduating Alpha Omega Alpha with a research focus in cardiothoracic and trauma surgery\, and earned an MBA from the Anderson School of Management at UCLA. \nMaria serves on the boards of Adient\, Aria CV\, AtaCor\, FineHeart\, Vascular Graft Solutions and Vectorious\, and previously served on the boards of Apama (acquired by Boston Scientific) and Capricor (NASD:CAPR). \nIn addition to her role at Broadview Ventures\, Maria contributes time as a SBIR/STTR grant reviewer for the National Science Foundation and is a Strategic Advisory Board Member for the RAD BioMed Accelerator in Tel Aviv\, Israel.
URL:https://scienceinboston.com/event/venture-funding-happy-hour-at-m2d2-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200205T080000
DTEND;TZID=America/New_York:20200205T100000
DTSTAMP:20260419T012836
CREATED:20200102T202143Z
LAST-MODIFIED:20200102T202143Z
UID:7674-1580889600-1580896800@scienceinboston.com
SUMMARY:Are Your Trade Secrets Walking Out The Door?
DESCRIPTION:Our panel of experts will discuss the increasingly important field of trade secret law in the Defend Trade Secrets Act era\, and provide guidance on how to protect your trade secrets and to maximize their value. Join us to learn and partake in the discussion about cutting-edge trade secret litigation\, the important considerations around whether to seek patent or trade secret protection for your invention\, the impact of the Defend Trade Secrets Act on the value of trade secrets\, and the future role of trade secrets in biotech and biopharma. \nWho should attend: \n\nChief executives\nChief operations officers\nChief financial officers\nGeneral Counsel\nScientists\nHuman Resources executives\nBusiness Development executives\n\nSponsored by the MassBio Forum Legal Working Group
URL:https://scienceinboston.com/event/are-your-trade-secrets-walking-out-the-door/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200205T080000
DTEND;TZID=America/New_York:20200205T100000
DTSTAMP:20260419T012836
CREATED:20200102T202143Z
LAST-MODIFIED:20200102T202143Z
UID:27427-1580889600-1580896800@scienceinboston.com
SUMMARY:Are Your Trade Secrets Walking Out The Door?
DESCRIPTION:Our panel of experts will discuss the increasingly important field of trade secret law in the Defend Trade Secrets Act era\, and provide guidance on how to protect your trade secrets and to maximize their value. Join us to learn and partake in the discussion about cutting-edge trade secret litigation\, the important considerations around whether to seek patent or trade secret protection for your invention\, the impact of the Defend Trade Secrets Act on the value of trade secrets\, and the future role of trade secrets in biotech and biopharma. \nWho should attend: \n\nChief executives\nChief operations officers\nChief financial officers\nGeneral Counsel\nScientists\nHuman Resources executives\nBusiness Development executives\n\nSponsored by the MassBio Forum Legal Working Group
URL:https://scienceinboston.com/event/are-your-trade-secrets-walking-out-the-door-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200225T080000
DTEND;TZID=America/New_York:20200225T100000
DTSTAMP:20260419T012836
CREATED:20200102T202403Z
LAST-MODIFIED:20200102T202403Z
UID:7676-1582617600-1582624800@scienceinboston.com
SUMMARY:Leading The Change To Continuous Manufacturing Of Small Molecules
DESCRIPTION:For more than a century\, pharmaceuticals have been assembled through a systematic step-by-step process known as batch manufacturing. Continuous Manufacturing (CM) facilitates production of the final dosage form in a single nonstop process with no equipment downtime. Although different approaches are being taken\, the goals are the same: promoting drug quality and improving the efficiency and yield of pharmaceutical manufacturing. \nToday\, with the support of CDER FDA\, under the leadership of Janet Woodcock\, MD\, there are four companies manufacturing five FDA approved products using CM\, treating diseases like cystic fibrosis\, HIV-1 infections\, breast cancer and leukemia. According to FDA\, about 20 additional companies have engaged them to support their efforts to convert to CM. \nMassachusetts has been at the forefront of this paradigm shift\, with its home-grown companies and academic institutions developing and commercializing innovative continuous solutions. In this forum we’ll explore where we are and what’s next with Continuous Manufacturing of small molecules and what companies should be doing. We’ll also hear how CM has the potential to transform the entire discovery\, development & manufacturing value chain from some visionary leaders. \nThis forum will focus on the following aspects of this ongoing industry transformation: \n\nWhat are the advantages/disadvantages of adopting continuous manufacturing? What is the risk of being left behind?\nWhat are the current barriers for implementation of continuous manufacturing?\nWhat is the Emerging Technologies Team (ETT) at CDER\, and their role in CM?\nHow should companies approach testing/adoption of this new platform?\nWhat is the role of supporting equipment\, e.g.\, Process Analytical Technologies (PATs)\, and control systems?\nEnd-to-end – when will this happen?\nWhat is the larger vision for continuous flow technology and autonomous reaction platforms?
URL:https://scienceinboston.com/event/leading-the-change-to-continuous-manufacturing-of-small-molecules/
LOCATION:Ragon Auditorium\, 400 Tech Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200225T080000
DTEND;TZID=America/New_York:20200225T100000
DTSTAMP:20260419T012836
CREATED:20200102T202403Z
LAST-MODIFIED:20200102T202403Z
UID:27428-1582617600-1582624800@scienceinboston.com
SUMMARY:Leading The Change To Continuous Manufacturing Of Small Molecules
DESCRIPTION:For more than a century\, pharmaceuticals have been assembled through a systematic step-by-step process known as batch manufacturing. Continuous Manufacturing (CM) facilitates production of the final dosage form in a single nonstop process with no equipment downtime. Although different approaches are being taken\, the goals are the same: promoting drug quality and improving the efficiency and yield of pharmaceutical manufacturing. \nToday\, with the support of CDER FDA\, under the leadership of Janet Woodcock\, MD\, there are four companies manufacturing five FDA approved products using CM\, treating diseases like cystic fibrosis\, HIV-1 infections\, breast cancer and leukemia. According to FDA\, about 20 additional companies have engaged them to support their efforts to convert to CM. \nMassachusetts has been at the forefront of this paradigm shift\, with its home-grown companies and academic institutions developing and commercializing innovative continuous solutions. In this forum we’ll explore where we are and what’s next with Continuous Manufacturing of small molecules and what companies should be doing. We’ll also hear how CM has the potential to transform the entire discovery\, development & manufacturing value chain from some visionary leaders. \nThis forum will focus on the following aspects of this ongoing industry transformation: \n\nWhat are the advantages/disadvantages of adopting continuous manufacturing? What is the risk of being left behind?\nWhat are the current barriers for implementation of continuous manufacturing?\nWhat is the Emerging Technologies Team (ETT) at CDER\, and their role in CM?\nHow should companies approach testing/adoption of this new platform?\nWhat is the role of supporting equipment\, e.g.\, Process Analytical Technologies (PATs)\, and control systems?\nEnd-to-end – when will this happen?\nWhat is the larger vision for continuous flow technology and autonomous reaction platforms?
URL:https://scienceinboston.com/event/leading-the-change-to-continuous-manufacturing-of-small-molecules-2/
LOCATION:Ragon Auditorium\, 400 Tech Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200226T080000
DTEND;TZID=America/New_York:20200227T160000
DTSTAMP:20260419T012836
CREATED:20200102T202707Z
LAST-MODIFIED:20200102T202707Z
UID:7679-1582704000-1582819200@scienceinboston.com
SUMMARY:8th Neurodegenerative Drug Development Summit
DESCRIPTION:Previously the World CNS Summit\, the Neurodegenerative Drug Development Summit returns to Boston to host over 150 neurodegeneration experts to enable them to overcome their translational challenges and successfully translate into the clinic. \nAcross 34 case-study-driven scientific presentations\, 5 interactive workshops and 2 parallel tracks of learning\, this meeting will deep-dive into the translational challenges faced by drug developers in this established industry and examine advances in new biomarker technologies\, the potential of gene therapy\, emerging targets and more. \nLeading organizations at the cutting edge of the field\, including Biogen\, AbbVie\, Sanofi and more\, are attending this meeting to share their progress and network for future collaborations. Don’t miss this opportunity immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
URL:https://scienceinboston.com/event/8th-neurodegenerative-drug-development-summit/
LOCATION:Hyatt Regency Boston\, 1 Ave de Lafayette\, Boston\, MA\, 02111\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200226T080000
DTEND;TZID=America/New_York:20200227T160000
DTSTAMP:20260419T012836
CREATED:20200102T202707Z
LAST-MODIFIED:20200102T202707Z
UID:27429-1582704000-1582819200@scienceinboston.com
SUMMARY:8th Neurodegenerative Drug Development Summit
DESCRIPTION:Previously the World CNS Summit\, the Neurodegenerative Drug Development Summit returns to Boston to host over 150 neurodegeneration experts to enable them to overcome their translational challenges and successfully translate into the clinic. \nAcross 34 case-study-driven scientific presentations\, 5 interactive workshops and 2 parallel tracks of learning\, this meeting will deep-dive into the translational challenges faced by drug developers in this established industry and examine advances in new biomarker technologies\, the potential of gene therapy\, emerging targets and more. \nLeading organizations at the cutting edge of the field\, including Biogen\, AbbVie\, Sanofi and more\, are attending this meeting to share their progress and network for future collaborations. Don’t miss this opportunity immerse yourself in the neurodegenerative community to help refresh the neurodegenerative approach and challenge traditional thinking to advance clinical progress.
URL:https://scienceinboston.com/event/8th-neurodegenerative-drug-development-summit-2/
LOCATION:Hyatt Regency Boston\, 1 Ave de Lafayette\, Boston\, MA\, 02111\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200227T090000
DTEND;TZID=America/New_York:20200228T170000
DTSTAMP:20260419T012836
CREATED:20200102T202840Z
LAST-MODIFIED:20200203T173233Z
UID:7683-1582794000-1582909200@scienceinboston.com
SUMMARY:AI Powered Drug Discovery and Manufacturing Conference 2020
DESCRIPTION:The potential of AI to revolutionize drug discovery and manufacturing has kindled significant research efforts across industry and academia. By bringing together thought leaders in these fields\, we aim to assess the current state-of-the-art and evaluate its real impact on drug discovery and manufacturing. The conference will present cutting-edge machine learning methods in this area\, identify key opportunities for using these technologies in biotech\, and discuss regulatory issues that these innovations bring. The expected audience will be academics\, industry scientists\, investors\, regulators\, government representative\, postdocs and students. We plan to have this event to be very interactive\, blending lectures\, panels\, and posters. \nLink to the official website: https://www.aidm.mit.edu/ \nView the agenda here: https://www.aidm.mit.edu/ouragenda \nRegister today: https://bit.ly/35z39xW
URL:https://scienceinboston.com/event/ai-powered-drug-discovery-and-manufacturing-conference-2020/
LOCATION:MIT Samberg Conference Center\, Salon I/T\, 50 Memorial Drive\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200227T090000
DTEND;TZID=America/New_York:20200228T170000
DTSTAMP:20260419T012836
CREATED:20200102T202840Z
LAST-MODIFIED:20200102T202840Z
UID:27430-1582794000-1582909200@scienceinboston.com
SUMMARY:AI Powered Drug Discovery and Manufacturing Conference 2020
DESCRIPTION:The potential of AI to revolutionize drug discovery and manufacturing has kindled significant research efforts across industry and academia. By bringing together thought leaders in these fields\, we aim to assess the current state-of-the-art and evaluate its real impact on drug discovery and manufacturing. The conference will present cutting-edge machine learning methods in this area\, identify key opportunities for using these technologies in biotech\, and discuss regulatory issues that these innovations bring. The expected audience will be academics\, industry scientists\, investors\, regulators\, government representative\, postdocs and students. We plan to have this event to be very interactive\, blending lectures\, panels\, and posters. \nLink to the official website: https://www.aidm.mit.edu/ \nView the agenda here: https://www.aidm.mit.edu/ouragenda \nRegister today: https://bit.ly/35z39xW
URL:https://scienceinboston.com/event/ai-powered-drug-discovery-and-manufacturing-conference-2020-2/
LOCATION:MIT Samberg Conference Center\, Salon I/T\, 50 Memorial Drive\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200228T100000
DTEND;TZID=America/New_York:20200228T123000
DTSTAMP:20260419T012836
CREATED:20200102T205030Z
LAST-MODIFIED:20200102T205030Z
UID:7685-1582884000-1582893000@scienceinboston.com
SUMMARY:2020 Rare Disease Day
DESCRIPTION:The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases\, which affect nearly 30 million Americans and countless others around the world. The event recognizes Rare Disease Day and the research being done in Massachusetts to treat and cure rare disease. Alone we are rare\, together we are strong. Our agenda feature two panels with different points of view of the issue: a patient panel\, which will discuss the struggles beyond diagnosis and treatment; and an industry panel\, which will focus on how the biotech and pharma industry is going beyond treatment to healing the whole patient\, as well as supporting the caregivers.
URL:https://scienceinboston.com/event/2020-rare-disease-day/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200228T100000
DTEND;TZID=America/New_York:20200228T123000
DTSTAMP:20260419T012836
CREATED:20200102T205030Z
LAST-MODIFIED:20200102T205030Z
UID:27431-1582884000-1582893000@scienceinboston.com
SUMMARY:2020 Rare Disease Day
DESCRIPTION:The last day of February has been designated as Rare Disease Day in Massachusetts to call attention to the public health issues associated with rare diseases\, which affect nearly 30 million Americans and countless others around the world. The event recognizes Rare Disease Day and the research being done in Massachusetts to treat and cure rare disease. Alone we are rare\, together we are strong. Our agenda feature two panels with different points of view of the issue: a patient panel\, which will discuss the struggles beyond diagnosis and treatment; and an industry panel\, which will focus on how the biotech and pharma industry is going beyond treatment to healing the whole patient\, as well as supporting the caregivers.
URL:https://scienceinboston.com/event/2020-rare-disease-day-2/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200309T080000
DTEND;TZID=America/New_York:20200312T170000
DTSTAMP:20260419T012836
CREATED:20200102T205334Z
LAST-MODIFIED:20200102T205334Z
UID:7688-1583740800-1584032400@scienceinboston.com
SUMMARY:Environmental Health Risk: Analysis and Applications
DESCRIPTION:A Risk Analysis Course \nRisk analysis is a scientific tool designed to help us determine the existence and extent of threats to human health\, provide information about how best to manage these risks\, and improve our ability to communicate with the public about the proper response to these hazards. \nThis continuing education course explores the principles of risk assessment\, risk management\, and risk communication\, ensuring you can identify\, explain\, and make decisions about risks to public health. You will learn how risk analysis is done\, how it is interpreted\, and how it influences regulatory decision-making. This program will provide you with the knowledge and skills to analyze how environmental hazards impact human health. \nThis program uses case studies\, lectures\, and small-group work to explore such topics as hazard identification\, toxicology and epidemiology in risk analysis\, risk perception\, risk communication\, life-cycle assessment\, and the interplay of risk management and the law. You will gain the skills needed to: \n\nPerform a broader\, nuanced risk assessment\nImprove the effectiveness of current risk assessment practices\nApply these concepts to diverse risk analysis and management issues\n\nDuring this executive education program\, you will explore the legal and policy framework which will inform the direction of risk analysis in upcoming years\, gain the skills needed to perform a quantitative risk assessment\, discuss key factors influencing the effectiveness of risk assessment and management\, and apply these concepts in local\, state\, federal\, or international settings. After completing the course\, you will be able to determine whether hazards pose an unacceptable risk to public health\, communicate effectively about health risks\, and utilize risk analysis to improve decision-making. \nWhat is Risk Analysis? \nRisk analysis involves risk assessment (identifying and characterizing hazards to public health)\, risk management (evaluating how to protect public health)\, and risk communication (understanding and explaining health risks). \nRisk analysis is used to protect the environment and public health by organizing and communicating knowledge about health risks within a framework useful for decision making. This analysis is used to inform regulatory policy and address concerns associated with health hazards in the environment. \nWhy is Risk Analysis Important? \nThe public is increasingly concerned about how their health is impacted by environmental hazards such as chemicals\, pollution\, and food-borne disease. This increased awareness has repercussions for governments\, health organizations\, and private companies\, all of which have a stake in protecting public health. Risk analysis is a useful framework for managing health risks. \nUnderstanding the nature of risks\, how people perceive threats to their health\, and how risk information is communicated and understood is imperative to ensuring the proper management of environmental health risks. \nPrivate corporations need to be able to understand and address the impact of their operations and products on consumers to ensure they are not harming public health. Through the effective use of risk assessment methodologies\, your organization can reduce the costs associated with regulatory non-compliance\, avoid legal issues stemming from consumer liability and safety problems\, and build organizational trust through their proactive management of potentially hazardous scenarios. \nRisk analysis skills are equally important to public health agencies\, as they must be able to review risk assessments conducted by industry or other agencies\, interpret their findings\, and prioritize governmental response to public health hazards. \nDevelop an Unmatched Network of Public Health Leaders \nProgram participants come from diverse backgrounds\, functions\, and organizations from around the world\, tied together by their commitment to understanding how to improve public health. By bringing together the various stakeholders involved in risk analysis and management\, this course offers a truly rich experience. This program offers a small\, personal setting where you will learn as much from your fellow continuing education participants as from program faculty as you exchange valuable insights and best practices. With over 30% of alumni coming from outside the United States and representing more than 30 different countries\, this is a truly global course. You will leave Harvard having developed a global network of leading peers you can rely on for guidance as you return home and implement what you learned. \nCourse Website
URL:https://scienceinboston.com/event/environmental-health-risk-analysis-and-applications/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200309T080000
DTEND;TZID=America/New_York:20200312T170000
DTSTAMP:20260419T012836
CREATED:20200102T205334Z
LAST-MODIFIED:20200102T205334Z
UID:27432-1583740800-1584032400@scienceinboston.com
SUMMARY:Environmental Health Risk: Analysis and Applications
DESCRIPTION:A Risk Analysis Course \nRisk analysis is a scientific tool designed to help us determine the existence and extent of threats to human health\, provide information about how best to manage these risks\, and improve our ability to communicate with the public about the proper response to these hazards. \nThis continuing education course explores the principles of risk assessment\, risk management\, and risk communication\, ensuring you can identify\, explain\, and make decisions about risks to public health. You will learn how risk analysis is done\, how it is interpreted\, and how it influences regulatory decision-making. This program will provide you with the knowledge and skills to analyze how environmental hazards impact human health. \nThis program uses case studies\, lectures\, and small-group work to explore such topics as hazard identification\, toxicology and epidemiology in risk analysis\, risk perception\, risk communication\, life-cycle assessment\, and the interplay of risk management and the law. You will gain the skills needed to: \n\nPerform a broader\, nuanced risk assessment\nImprove the effectiveness of current risk assessment practices\nApply these concepts to diverse risk analysis and management issues\n\nDuring this executive education program\, you will explore the legal and policy framework which will inform the direction of risk analysis in upcoming years\, gain the skills needed to perform a quantitative risk assessment\, discuss key factors influencing the effectiveness of risk assessment and management\, and apply these concepts in local\, state\, federal\, or international settings. After completing the course\, you will be able to determine whether hazards pose an unacceptable risk to public health\, communicate effectively about health risks\, and utilize risk analysis to improve decision-making. \nWhat is Risk Analysis? \nRisk analysis involves risk assessment (identifying and characterizing hazards to public health)\, risk management (evaluating how to protect public health)\, and risk communication (understanding and explaining health risks). \nRisk analysis is used to protect the environment and public health by organizing and communicating knowledge about health risks within a framework useful for decision making. This analysis is used to inform regulatory policy and address concerns associated with health hazards in the environment. \nWhy is Risk Analysis Important? \nThe public is increasingly concerned about how their health is impacted by environmental hazards such as chemicals\, pollution\, and food-borne disease. This increased awareness has repercussions for governments\, health organizations\, and private companies\, all of which have a stake in protecting public health. Risk analysis is a useful framework for managing health risks. \nUnderstanding the nature of risks\, how people perceive threats to their health\, and how risk information is communicated and understood is imperative to ensuring the proper management of environmental health risks. \nPrivate corporations need to be able to understand and address the impact of their operations and products on consumers to ensure they are not harming public health. Through the effective use of risk assessment methodologies\, your organization can reduce the costs associated with regulatory non-compliance\, avoid legal issues stemming from consumer liability and safety problems\, and build organizational trust through their proactive management of potentially hazardous scenarios. \nRisk analysis skills are equally important to public health agencies\, as they must be able to review risk assessments conducted by industry or other agencies\, interpret their findings\, and prioritize governmental response to public health hazards. \nDevelop an Unmatched Network of Public Health Leaders \nProgram participants come from diverse backgrounds\, functions\, and organizations from around the world\, tied together by their commitment to understanding how to improve public health. By bringing together the various stakeholders involved in risk analysis and management\, this course offers a truly rich experience. This program offers a small\, personal setting where you will learn as much from your fellow continuing education participants as from program faculty as you exchange valuable insights and best practices. With over 30% of alumni coming from outside the United States and representing more than 30 different countries\, this is a truly global course. You will leave Harvard having developed a global network of leading peers you can rely on for guidance as you return home and implement what you learned. \nCourse Website
URL:https://scienceinboston.com/event/environmental-health-risk-analysis-and-applications-2/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200316T080000
DTEND;TZID=America/New_York:20200319T170000
DTSTAMP:20260419T012836
CREATED:20200102T205545Z
LAST-MODIFIED:20200102T205545Z
UID:7690-1584345600-1584637200@scienceinboston.com
SUMMARY:Management and Leadership Skills for Environmental Health and Safety Professionals
DESCRIPTION:Improving environmental health and safety performance within your organization requires an in-depth understanding of management principles and the leadership skills to drive change. You need to be able to build leadership buy-in for health\, safety\, and environmental initiatives\, lead teams effectively\, and create strategies for integrating EHS principles into the culture of your organization. \nIn this course\, you will develop the management skills needed to improve the EHS function in your organization while gaining the leadership skills needed to lead teams\, make decisions\, build stakeholder buy-in\, and generate and sustain change. You will participate in focused skill building in the critical areas of leadership and management development with the objective of bridging the gap between environmental health and safety technical skills and leadership skills essential for achieving functional excellence. \nManagement Training for EHS Professionals \nAs you move higher in your organization\, the requirements for technical environmental health skills give way to requirements for management skills. You will need to develop clear goals and objectives that tie environmental health and safety outcomes to organizational goals\, develop strategies to achieve these objectives\, establish expectations\, delegate to team members\, and measure outcomes. \nIn this course you will learn principles imperative to your success as a manager\, including: \n\nManaging and motivating people\nNegotiation and conflict resolution\nEffective business communication\nRisk communication\nListening as a communication skill\nTime management and utilization\nStrategic and business planning for results\nRegulatory affairs management\nProfessional ethics and legal issues of management\nBuilding EHS management systems\n\nThe management skills you learn in this training will make you a more effective environmental health professional while also developing your proficiency in influencing the actions of others. This skillset will allow you to lead others\, manage yourself better\, and make better decisions. \nLeadership Skills for Environmental Health and Safety Professionals \nGenerating and sustaining long-term change in an organization requires moving beyond management to leadership. Unlike managers\, leaders are not limited by the scope of their formal authority. They influence and guide others across traditional organizational boundaries\, build relationships\, and overcome organization-wide challenges to increasing productivity and value. \nThis course covers both functional leadership\, a form of leadership focused on effectiveness and cohesion\, and transformational leadership which is focused on creating and sustaining change. Both types of leadership are required in today’s complex business environment. \nThis leadership development course will help you work smarter\, make strategic contributions to your organization\, and gain increased respect\, rewards\, and recognition. \nLearn From and Network With Environmental Health and Safety Professionals \nProgram participants come from diverse backgrounds\, functions\, and organizations from around the world\, tied together by their desire to become a leader in environmental health and safety. By bringing together EHS managers and leaders from around the world\, this course offers a truly rich experience. This training program offers a small\, personal setting where you will learn as much from your fellow participants as from program faculty as you exchange valuable insights and best practices. You will leave Harvard having developed a global network of leading peers you can rely on for guidance as you return home and implement what you learned. \nCourse Website
URL:https://scienceinboston.com/event/management-and-leadership-skills-for-environmental-health-and-safety-professionals/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200316T080000
DTEND;TZID=America/New_York:20200319T170000
DTSTAMP:20260419T012836
CREATED:20200102T205545Z
LAST-MODIFIED:20200102T205545Z
UID:27433-1584345600-1584637200@scienceinboston.com
SUMMARY:Management and Leadership Skills for Environmental Health and Safety Professionals
DESCRIPTION:Improving environmental health and safety performance within your organization requires an in-depth understanding of management principles and the leadership skills to drive change. You need to be able to build leadership buy-in for health\, safety\, and environmental initiatives\, lead teams effectively\, and create strategies for integrating EHS principles into the culture of your organization. \nIn this course\, you will develop the management skills needed to improve the EHS function in your organization while gaining the leadership skills needed to lead teams\, make decisions\, build stakeholder buy-in\, and generate and sustain change. You will participate in focused skill building in the critical areas of leadership and management development with the objective of bridging the gap between environmental health and safety technical skills and leadership skills essential for achieving functional excellence. \nManagement Training for EHS Professionals \nAs you move higher in your organization\, the requirements for technical environmental health skills give way to requirements for management skills. You will need to develop clear goals and objectives that tie environmental health and safety outcomes to organizational goals\, develop strategies to achieve these objectives\, establish expectations\, delegate to team members\, and measure outcomes. \nIn this course you will learn principles imperative to your success as a manager\, including: \n\nManaging and motivating people\nNegotiation and conflict resolution\nEffective business communication\nRisk communication\nListening as a communication skill\nTime management and utilization\nStrategic and business planning for results\nRegulatory affairs management\nProfessional ethics and legal issues of management\nBuilding EHS management systems\n\nThe management skills you learn in this training will make you a more effective environmental health professional while also developing your proficiency in influencing the actions of others. This skillset will allow you to lead others\, manage yourself better\, and make better decisions. \nLeadership Skills for Environmental Health and Safety Professionals \nGenerating and sustaining long-term change in an organization requires moving beyond management to leadership. Unlike managers\, leaders are not limited by the scope of their formal authority. They influence and guide others across traditional organizational boundaries\, build relationships\, and overcome organization-wide challenges to increasing productivity and value. \nThis course covers both functional leadership\, a form of leadership focused on effectiveness and cohesion\, and transformational leadership which is focused on creating and sustaining change. Both types of leadership are required in today’s complex business environment. \nThis leadership development course will help you work smarter\, make strategic contributions to your organization\, and gain increased respect\, rewards\, and recognition. \nLearn From and Network With Environmental Health and Safety Professionals \nProgram participants come from diverse backgrounds\, functions\, and organizations from around the world\, tied together by their desire to become a leader in environmental health and safety. By bringing together EHS managers and leaders from around the world\, this course offers a truly rich experience. This training program offers a small\, personal setting where you will learn as much from your fellow participants as from program faculty as you exchange valuable insights and best practices. You will leave Harvard having developed a global network of leading peers you can rely on for guidance as you return home and implement what you learned. \nCourse Website
URL:https://scienceinboston.com/event/management-and-leadership-skills-for-environmental-health-and-safety-professionals-2/
LOCATION:Harvard T.H. Chan School of Public Health\, FXB Building 651 Huntington Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200324T130000
DTEND;TZID=America/New_York:20200324T170000
DTSTAMP:20260419T012836
CREATED:20200323T181751Z
LAST-MODIFIED:20200323T181751Z
UID:8516-1585054800-1585069200@scienceinboston.com
SUMMARY:Artificial Intelligence and Disability/Dependency: Equity\, Access\, and Interdependence
DESCRIPTION:Online Viewing\nIn light of the rapidly developing COVID-19 outbreaks\, Harvard University has restricted on-campus events. As a result\, we will not be allowing in-person attendance at this event. Instead\, the event will be available for viewing online. To ensure that you will receive access to the livestream and be kept up to date on any changes to the event\, register now. We will send out a link to the livestream of the event to all registrants three days before the conference. \nHosting events\, even ones that are largely virtual\, is a constantly moving target these days and we appreciate your patience and flexibility as we fine tune our approach. In the meantime\, we hope you all stay well. \nDescription\nThis event will highlight the challenges and opportunities in harnessing artificial intelligence (AI) technologies to serve the needs of individuals with disabilities and dependencies. AI can improve the lives of people with disabilities\, such as smart devices supporting people with physical disabilities or sight loss.  On the other hand\, AI outputs can also reflect discriminatory biases present in the underlying data used to develop the algorithms. While this “garbage in\, garbage out” principle is well documented in respect to AI and gender or race\, it is understudied in respect to disability or dependencies. \nInterdisciplinary panels of legal scholars\, ethicists\, AI developers\, medical and service providers\, and advocates with disabilities/ dependencies will explore best practices and guidelines for stakeholders\, guided by ethical principles\, legal considerations\, and the needs of people with disabilities/ dependencies. Participants will seek to articulate clear criteria for developers and medical providers looking to harness the potential of AI to serve individuals with disabilities/ dependencies\, including those whose disabilities/ dependencies are the result of aging\, injury\, or disease\, and the caregivers — including both professionals and unpaid friends and families — who support some of these individuals. \nAgenda\n1:00 – 2:00pm\, Panel 1: AI and Disability\n\nBetsy Beaumon\, CEO\, Benetech\nNoll Campbell\, Research Scientist\, Indiana University Center for Aging Research at Regenstrief Institute and Assistant Professor\, Department of Pharmacy Practice\, Purdue University College of Pharmacy\nJennifer Hawkins\, Associate Research Professor\, Department of Philosophy\, Duke University\nModerator: Michael Ashley Stein\, Executive Director\, Harvard Law School Project on Disability and Visiting Professor\, Harvard Law School\n\n2:00 – 3:00pm\, Keynote\n\nGeralyn Miller\, Director of Health Strategy\, Microsoft AI for Good Research Lab\n\n3:00 – 3:45pm\, Panel 2: AI and Dependency\n\nSharona Hoffman\, Edgar A. Hahn Professor of Law\, School of Law\, Co-Director\, The Law-Medicine Center\, School of Law\, and Professor\, Department of Bioethics\, School of Medicine\, Case Western Reserve University\nAri Ne’eman\, PhD Student in Health Policy\, Harvard University\, and founder\, Autistic Self Advocacy Network\nRanak Trivedi\, Assistant Professor of Psychiatry and Behavior Sciences\, Stanford University\nModerator: Sonoo Thadaney\, Executive Director\, Stanford Presence and Executive Director\, Program in Bedside Medicine\n\nJoin us online!\nThis event is free and can be viewed online by the public\, but registration is required. Register now!
URL:https://scienceinboston.com/event/artificial-intelligence-and-disability-dependency-equity-access-and-interdependence/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200324T130000
DTEND;TZID=America/New_York:20200324T170000
DTSTAMP:20260419T012836
CREATED:20200323T181751Z
LAST-MODIFIED:20200323T181751Z
UID:27440-1585054800-1585069200@scienceinboston.com
SUMMARY:Artificial Intelligence and Disability/Dependency: Equity\, Access\, and Interdependence
DESCRIPTION:Online Viewing\nIn light of the rapidly developing COVID-19 outbreaks\, Harvard University has restricted on-campus events. As a result\, we will not be allowing in-person attendance at this event. Instead\, the event will be available for viewing online. To ensure that you will receive access to the livestream and be kept up to date on any changes to the event\, register now. We will send out a link to the livestream of the event to all registrants three days before the conference. \nHosting events\, even ones that are largely virtual\, is a constantly moving target these days and we appreciate your patience and flexibility as we fine tune our approach. In the meantime\, we hope you all stay well. \nDescription\nThis event will highlight the challenges and opportunities in harnessing artificial intelligence (AI) technologies to serve the needs of individuals with disabilities and dependencies. AI can improve the lives of people with disabilities\, such as smart devices supporting people with physical disabilities or sight loss.  On the other hand\, AI outputs can also reflect discriminatory biases present in the underlying data used to develop the algorithms. While this “garbage in\, garbage out” principle is well documented in respect to AI and gender or race\, it is understudied in respect to disability or dependencies. \nInterdisciplinary panels of legal scholars\, ethicists\, AI developers\, medical and service providers\, and advocates with disabilities/ dependencies will explore best practices and guidelines for stakeholders\, guided by ethical principles\, legal considerations\, and the needs of people with disabilities/ dependencies. Participants will seek to articulate clear criteria for developers and medical providers looking to harness the potential of AI to serve individuals with disabilities/ dependencies\, including those whose disabilities/ dependencies are the result of aging\, injury\, or disease\, and the caregivers — including both professionals and unpaid friends and families — who support some of these individuals. \nAgenda\n1:00 – 2:00pm\, Panel 1: AI and Disability\n\nBetsy Beaumon\, CEO\, Benetech\nNoll Campbell\, Research Scientist\, Indiana University Center for Aging Research at Regenstrief Institute and Assistant Professor\, Department of Pharmacy Practice\, Purdue University College of Pharmacy\nJennifer Hawkins\, Associate Research Professor\, Department of Philosophy\, Duke University\nModerator: Michael Ashley Stein\, Executive Director\, Harvard Law School Project on Disability and Visiting Professor\, Harvard Law School\n\n2:00 – 3:00pm\, Keynote\n\nGeralyn Miller\, Director of Health Strategy\, Microsoft AI for Good Research Lab\n\n3:00 – 3:45pm\, Panel 2: AI and Dependency\n\nSharona Hoffman\, Edgar A. Hahn Professor of Law\, School of Law\, Co-Director\, The Law-Medicine Center\, School of Law\, and Professor\, Department of Bioethics\, School of Medicine\, Case Western Reserve University\nAri Ne’eman\, PhD Student in Health Policy\, Harvard University\, and founder\, Autistic Self Advocacy Network\nRanak Trivedi\, Assistant Professor of Psychiatry and Behavior Sciences\, Stanford University\nModerator: Sonoo Thadaney\, Executive Director\, Stanford Presence and Executive Director\, Program in Bedside Medicine\n\nJoin us online!\nThis event is free and can be viewed online by the public\, but registration is required. Register now!
URL:https://scienceinboston.com/event/artificial-intelligence-and-disability-dependency-equity-access-and-interdependence-2/
LOCATION:Online
END:VEVENT
END:VCALENDAR